Pneumococcal vaccination in adults: Rationale, state of the art and perspectives

Journal of Preventive Medicine and Hygiene

Volumn 53, Issue 2, 2012, Pages 78-84

  Icardi, G ^a   Sticchi, L ^a   Bagnasco, A ^a   Iudici, R ^a   Durando, P ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Adult; Elderly; Pneumococcal conjugate vaccine; Pneumococcal polysaccharide vaccine; Streptococcus pneumoniae

Indexed keywords

IMMUNOGLOBULIN G2; PNEUMOCOCCUS VACCINE;

BLOOD CULTURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; DISEASE ASSOCIATION; DRUG EFFICACY; FOLLOW UP; HALF LIFE TIME; HEALTH CARE COST; HOSPITAL ADMISSION; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; INCIDENCE; INFECTION PREVENTION; LABORATORY TEST; MORTALITY; OUTPATIENT CARE; PATIENT MONITORING; PNEUMOCOCCAL INFECTION; REVIEW; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

AGED; HUMANS; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE;

EID: 84864719960     PISSN: 11212233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Health Protection Agency. Centre for Infections, London, UK. Invasive Pneumococcal Disease (IPD) in England & Wales after 7-valent conjugate vaccine (PCV7); potential impact of 10 and 13-valent vaccines. Available at http://www.hpa.org.uk/web/HPAwebFile/HPAweb-C/1245581527892.
2. Weycker D, Strutton D, Edelsberg J, et al. Clinical and economic burden of pneumococcal disease in older US adults. Vaccine 2010;28:4955-60.
3. Pilishvili T, Lexau C, Farley M, et al. Sustained reductions in invasive pneumoccoal disease in the era of conjugate vaccine. J Inf Dis 2010;201:302-41.
4. Durando P, Crovari P, Ansaldi F, et al. Universal childhood immunisation against Streptococcus pneumoniae: the five-year experience of Liguria Region, Italy. Vaccine 2009;27:3459-62.
5. Lexau CA, Lynfield R, Danila R, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005;294:2043-51. (Pubitemid 41539937)
6. Grijalva CG, Nuorti JP, Arbogast PG, et al. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007;369:1179-86. (Pubitemid 46527876)
7. Resti M, Micheli A, Moriondo M, et al. Comparison of the effect of antibiotic treatment on the possibility of diagnosing invasive pneumococcal disease by culture or molecular methods: a prospective, observational study of children and adolescents with proven pneumococcal infection. Clin Ther 2009;31:1266-73.
8. Nelson JC, Jackson M, Yu O, et al. Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults. Vaccine 2008; 26:4947-54.
9. Huang SS, Johnson KM, Ray GT, et al. Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine 2011; 29:3398-412.
10. Almirall J, Bolíbar I, Vidal J, et al. Epidemiology of community-acquired pneumonia in adults: a population-based study. Eur Respir J 2000;15:757-63. (Pubitemid 30196306)
11. Jokinen C, Heiskanen L, Juvonen H, et al. Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. Am J Epidemiol 1993;137:977-88. (Pubitemid 23191065)
12. Gutiérrez F, Masiá M, Mirete C, et al. The influence of age and gender on the population-based incidence of community-acquired pneumonia caused by different microbial pathogens. J Infect 2006;53:166-74. (Pubitemid 44227814)
13. Ewig S, Birkner N, Strauss R, et al. New perspectives on community-acquired pneumonia in 388406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax 2009;64:1062-9.
14. Marston BJ, Plouffe JF, File TM Jr, et al. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med 1997;157:1709-18. (Pubitemid 27327407)
15. Jackson ML, Neuzil KM, Thompson WW, et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis 2004;39:1642-50. (Pubitemid 39578539)
16. rd ed. Philadelphia: WB Saunders 1999, pp. 215-219.
17. Gil-Prieto R, García-García L, Alvaro-Meca A, et al. The burden of hospitalisations for community-acquired pneumonia (CAP) and pneumococcal pneumonia in adults in Spain (2003-2007). Vaccine 2011;29:412-6.
18. Giorgi Rossi P, Agabiti N, Faustini A, et al. The burden of hospitalized pneumonia in Lazio, Italy, 1997-1999. Int J Tuberc Lung Dis 2004;8:528-36. (Pubitemid 38625057)
19. D'Alessandro D, Cerquetani F, Proietti F, et al. Andamento della mortalità per polmoniti in Italia nel periodo 1975-1994. Ann Ig 1999;11:251-260.
20. Ministero della Salute. Circolare n. 11 del 19 Novembre 2001. Vaccinazione antipneumococcica in età pediatrica.
21. Ministero della Salute. Circolare del 29 Luglio 2010. Circolare Prevenzione e controllo dell'influenza: raccomandazioni per la stagione 2010-2011.
22. French N. Use of pneumococcal polysaccharide vaccines: no simple answers. J Infect 2003;46:78-86. (Pubitemid 36221653)
23. WHO position paper. 23-valent pneumococcal polysaccharide vaccine. Wkly Epidemiol Rec 2008;83:373-84.
24. Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep 2010;59:1102-6.
25. Moberley SA, Holden J, Tatham DP, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008;(1):CD000422.
26. Walters JA, Smith S, Poole P, et al. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2010;(11):CD001390.
27. European Medicines Agency (EMA). Available at http://www.ema.europa.eu/ ema/index.jsp?curl=pages/medicines/human/medicines/001104/smops/Positive/ human-smop-000294.jsp&mid=WC0b01ac058001d127.